Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-7685
Authors: Desai, Hardik D.
Sharma, Kamal
Shah, Anchal
Patoliya, Jaimini
Patil, Anant
Hooshanginezhad, Zahra
Grabbe, Stephan
Goldust, Mohamad
Title: Can SARS-CoV-2 vaccine increase the risk of reactivation of Varicella zoster? : A systematic review
Online publication date: 6-Sep-2022
Year of first publication: 2021
Language: english
Abstract: Introduction Although the COVID-19 vaccination is deemed safe, exact incidence and nature if adverse effects, particularly dermatological ones, are still unknown. Objective To describe the demographic, clinical, morphological characteristics, outcomes, and timing of development of herpes zoster to the various COVID-19 vaccines. And to identify on whether COVID-19 vaccine has temporal relationship between development of herpes zoster (HZ). Methods We have performed a systemic review of articles from PubMed and Embase using MeSH and keywords like “Shingles,” “Herpes zoster,” “Varicella zoster,” “COVID-19,” “Vaccine,” “SARS-CoV-2.” No filters including country of publication, language, type of articles were applied. Individual case report references were filtered for any pertinent cases. Results A total of 54 cases consisting of 27 male and 27 female patients have been reported. There were cases with known risk factors for herpes zoster, which included age more than 50 years (n = 36), immunological disorders (n = 10), chronic disease (n = 25), metabolic disorder (n = 13), malignancy (n = 4), and psychiatric disorder (n = 2). The mean (SD) period between development of herpes zoster and COVID-19 vaccination was 7.64 (6.92) days. Majority of the cases were from the high-income and/or middle-income countries. 86.27% of the cases of HZ were reported due to mRNA vaccine. Thirty-six patients 36/45 (80%) developed herpes zoster following the priming dose of COVID-19 vaccine among those who received mRNA vaccine. Conclusion We could not establish definite link but there may be possible association between COVID-19 vaccine and shingles. Large-scale studies may help to understand the cause-effect relationship.
DDC: 610 Medizin
610 Medical sciences
Institution: Johannes Gutenberg-Universität Mainz
Department: FB 04 Medizin
Place: Mainz
ROR: https://ror.org/023b0x485
DOI: http://doi.org/10.25358/openscience-7685
Version: Published version
Publication type: Zeitschriftenaufsatz
License: CC BY-NC
Information on rights of use: https://creativecommons.org/licenses/by-nc/4.0/
Journal: Journal of cosmetic dermatology
20
11
Pages or article number: 3350
3361
Publisher: Wiley-Blackwell
Publisher place: Oxford
Issue date: 2021
ISSN: 1473-2165
Publisher DOI: 10.1111/jocd.14521
Appears in collections:JGU-Publikationen

Files in This Item:
  File Description SizeFormat
Thumbnail
can_sarscov2_vaccine_increase-20220906120228657.pdf364.05 kBAdobe PDFView/Open